408 related articles for article (PubMed ID: 7648773)
1. Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease.
Clipp EC; Moore MJ
Clin Pharmacol Ther; 1995 Aug; 58(2):228-36. PubMed ID: 7648773
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
Antuono PG
Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110
[TBL] [Abstract][Full Text] [Related]
3. The effects of galantamine treatment on caregiver time in Alzheimer's disease.
Sano M; Wilcock GK; van Baelen B; Kavanagh S
Int J Geriatr Psychiatry; 2003 Oct; 18(10):942-50. PubMed ID: 14533127
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
Davis KL; Thal LJ; Gamzu ER; Davis CS; Woolson RF; Gracon SI; Drachman DA; Schneider LS; Whitehouse PJ; Hoover TM
N Engl J Med; 1992 Oct; 327(18):1253-9. PubMed ID: 1406817
[TBL] [Abstract][Full Text] [Related]
5. [Predictors of long-term institutionalization in patients with Alzheimer's disease: role of caregiver burden].
Hirono N; Tsukamoto N; Inoue M; Moriwaki Y; Mori E
No To Shinkei; 2002 Sep; 54(9):812-8. PubMed ID: 12428367
[TBL] [Abstract][Full Text] [Related]
6. [Impact of music therapy on anxiety and depression for patients with Alzheimer's disease and on the burden felt by the main caregiver (feasibility study)].
Guetin S; Portet F; Picot MC; Defez C; Pose C; Blayac JP; Touchon J
Encephale; 2009 Feb; 35(1):57-65. PubMed ID: 19250995
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
8. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
[TBL] [Abstract][Full Text] [Related]
9. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study.
Chiu CC; Su KP; Cheng TC; Liu HC; Chang CJ; Dewey ME; Stewart R; Huang SY
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1538-44. PubMed ID: 18573585
[TBL] [Abstract][Full Text] [Related]
10. The cardinal features of cognitive and noncognitive dysfunction and the differential efficacy of tacrine in Alzheimer's disease patients.
Talwalker S
J Biopharm Stat; 1996 Nov; 6(4):443-56. PubMed ID: 8969979
[TBL] [Abstract][Full Text] [Related]
11. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study.
Gutzmann H; Kühl KP; Hadler D; Rapp MA
Pharmacopsychiatry; 2002 Jan; 35(1):12-8. PubMed ID: 11819153
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled trial of modafinil for the treatment of apathy in individuals with mild-to-moderate Alzheimer's disease.
Frakey LL; Salloway S; Buelow M; Malloy P
J Clin Psychiatry; 2012 Jun; 73(6):796-801. PubMed ID: 22687392
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial.
Scheltens P; Kamphuis PJ; Verhey FR; Olde Rikkert MG; Wurtman RJ; Wilkinson D; Twisk JW; Kurz A
Alzheimers Dement; 2010 Jan; 6(1):1-10.e1. PubMed ID: 20129316
[TBL] [Abstract][Full Text] [Related]
15. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.
Farlow M; Gracon SI; Hershey LA; Lewis KW; Sadowsky CH; Dolan-Ureno J
JAMA; 1992 Nov; 268(18):2523-9. PubMed ID: 1404819
[TBL] [Abstract][Full Text] [Related]
16. Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group.
Zemlan FP
J Neural Transm (Vienna); 1996; 103(8-9):1105-16. PubMed ID: 9013398
[TBL] [Abstract][Full Text] [Related]
17. Does cognitive impairment influence burden in caregivers of patients with Alzheimer's disease?
Germain S; Adam S; Olivier C; Cash H; Ousset PJ; Andrieu S; Vellas B; Meulemans T; Reynish E; Salmon E;
J Alzheimers Dis; 2009; 17(1):105-14. PubMed ID: 19494435
[TBL] [Abstract][Full Text] [Related]
18. Mixed-model analysis of incomplete longitudinal data from a high-dose trial of tacrine (Cognex) in Alzheimer's patients.
Smith F
J Biopharm Stat; 1996 Mar; 6(1):59-67. PubMed ID: 8838779
[TBL] [Abstract][Full Text] [Related]
19. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.
Knapp MJ; Knopman DS; Solomon PR; Pendlebury WW; Davis CS; Gracon SI
JAMA; 1994 Apr; 271(13):985-91. PubMed ID: 8139083
[TBL] [Abstract][Full Text] [Related]
20. Velnacrine for Alzheimer's disease.
Birks J; Wilcock GG
Cochrane Database Syst Rev; 2004; (2):CD004748. PubMed ID: 15106259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
